We boldly develop novel therapeutics utilizing mRNA-based cell engineering and complex cytokines.

Our Focus

Brooklyn ImmunoTherapeutics (BTX) is committed to creating a world in which patients and families with high unmet medical needs have access to effective treatments. To achieve this, we are focused on three primary approaches:

iPSC-derived, iMSC therapeutics

In vivo gene editing therapeutics

Complex human-derived mixed cytokines

Latest News